Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners with the NHS.
In addition to your role at Sandoz, you are also one of the founding members of the British Biosimilars Association (BBA). Can you start by giving us the rationale behind setting up the BBA and the role that you think biosimilars can bring in driving innovation?
"The generics industry brings an enormous amount of value to the UK economy, to patients, to the NHS, and to everything around these products."
